Amicus Therapeutics(US:FOLD) Globenewswireยท2025-11-04 12:00Core Insights - Amicus Therapeutics reported a total revenue of $169.1 million for Q3 2025, reflecting a 17% increase at constant exchange rates (CER) [4][3] - The company achieved a positive GAAP net income of $17.3 million, compared to a net loss of $6.7 million in Q3 2024 [7][27] - Cash position increased to $264 million, marking a $33 million rise in Q3 2025 [4][7] Financial Performance - Total revenues for Q3 2025 were $169.1 million, with a year-over-year growth of 19% reported and 17% at CER [4][5] - Galafold sales reached $138.3 million, a 15% increase year-over-year, while Pombiliti + Opfolda sales were $30.7 million, up 45% year-over-year [7][5] - Total GAAP operating expenses were $115.3 million, an 8% increase from $106.6 million in Q3 2024 [7][27] Product Performance - Galafold's net product sales for Q3 2025 were $138.3 million, with a 12% growth at CER [7][5] - Pombiliti + Opfolda saw a significant increase in sales, driven by high demand and new market entries, achieving a 42% growth at CER [7][5] - The company is on track for full enrollment in the Phase 3 study of DMX-200 by year-end 2025 [3][14] Strategic Outlook - Amicus anticipates total revenue growth of 15% to 22% for 2025, with Galafold revenue growth projected at 10% to 15% and Pombiliti + Opfolda at 50% to 65% [8][4] - The company aims to achieve sustainable double-digit growth in the coming years, with a target of surpassing $1 billion in total sales by 2028 [14][3] - Amicus continues to focus on expanding its commercial business and enhancing its product pipeline for rare diseases [22][3]